Vnitr Lek 2014, 60(4):348-353

Acute heart failure and cardiogenic shock - trends at the beginning of 21st century

Richard Rokyta
Kardiologické oddělení, Komplexní kardiovaskulární centrum FN Plzeň, LF UK, přednosta prof. MUDr. Richard Rokyta, Ph.D.

Acute heart failure (AHF) is a clinical syndrome of different etiology and several clinical presentations. Cardiogenic shock patients have highest long-term mortality. In contrast to chronic heart failure, we have no evidence of therapeutic benefit for any treatment strategy from randomized clinical trials. Search for new pharmacologic and non-pharmacologic therapies is ongoing. Both causal and symptomatic treatment of AHF episode should be initiated as soon as possible. This review is focused on trends in acute heart failure therapy at the beginning of 21st century.

Keywords: acute coronary syndrome; acute heart failure; acute myocardial infarction; cardiogenic shock; mechanical circulatory support

Received: February 7, 2014; Published: April 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rokyta R. Acute heart failure and cardiogenic shock - trends at the beginning of 21st century. Vnitr Lek. 2014;60(4):348-353.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Teerlink JR, Cotter G, Davison BA et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381 (9860): 29-39. Go to original source... Go to PubMed...
    2. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33(14): 1787-1847. Go to original source... Go to PubMed...
    3. Hradec J, Vítovec J, Špinar J. Summary of the ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Prepared by the Czech Society of Cardiology. Cor et Vasa 2013; 55(1): e25-e40. Go to original source...
    4. Georghiade M, Follath F, Ponikowski P et al. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010; 12(5): 423-433. Go to original source... Go to PubMed...
    5. Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev 2007; 12(2): 87-90. Go to original source... Go to PubMed...
    6. Nieminen MS, Brutsaert D, Dickstein K et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27(22): 2725-2736. Go to original source... Go to PubMed...
    7. Goodlin SJ. Palliative care in congestive heart failure. J Am Coll Cardiol 2009; 54(5): 386-396. Go to original source... Go to PubMed...
    8. Felker GM, Lee KL, Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364(9): 797-805. Go to original source... Go to PubMed...
    9. Paterna S, Fazullo S, Parrinello G et al. Short-term effect of hypertonic saline solution in acute heart failure and long-term effect of a moderate podium restriction in patients with compensated heart failure with NYHA III (Class C) (SMAC-HF Study). Am J Med Sci 2011; 342(1): 27-37. Go to original source... Go to PubMed...
    10. Konstam MA, Gheorghiade M, Burnett jr. JC et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297(12): 1319-1331. Go to original source... Go to PubMed...
    11. O'Connor CM, Gattis WA, Adams jr. KF et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003; 41(9): 1452-1457. Go to original source... Go to PubMed...
    12. McMurray JJ, Teerlink JR, Cotter G et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007; 289(17): 2009-2019. Go to original source... Go to PubMed...
    13. Teerlink JR, Iragui VJ, Mohr JP et al. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf 2012; 35(3): 233-244. Go to original source... Go to PubMed...
    14. Givertz MM, Teerlink JR, Albert NM et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail 2013; 19(6): 371-389. Go to original source... Go to PubMed...
    15. Cleland JG, Freemantle N, Coletta AP et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006; 8(1): 105-110. Go to original source... Go to PubMed...
    16. Mebazaa A, Nieminen MS, Packer M et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297(17): 1883-1891. Go to original source... Go to PubMed...
    17. Aliti GB, Rabelo ER, Clausell N et al. Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial. JAMA Intern Med 2013; 173(12): 1058-1064. Go to original source... Go to PubMed...
    18. Gray AJ, Goodacre S, Newby DE et al. A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO trial. Health Technol Assess 2009; 13(33): 1-106. Go to original source... Go to PubMed...
    19. Weng CL, Zhao YT, Liu QH et al. Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med 2010; 152(9): 590-600. Go to original source... Go to PubMed...
    20. Costanzo MR, Saltzberg MT, Jessup M et al. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Card Fail 2010; 16(4): 277-284. Go to original source... Go to PubMed...
    21. Bart BA, Goldsmith SR, Lee KL et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367(24): 2296-2304. Go to original source... Go to PubMed...
    22. Babaev A, Frederick PD, Pasta DJ et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005; 294(4): 448-454. Go to original source... Go to PubMed...
    23. Widimsky P, Kala P. Summary of the 2012 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevations. Prepared by the Czech Society of Cardiology. Cor et Vasa 2012; 54: e273-e289. Go to original source...
    24. Bernat I, Abdelaal E, Plourde G et al. Early and late outcomes after primary percutaneous coronary intervention by radial or femoral approach in patients presenting in acute ST-elevation myocardial infarction and cardiogenic shock. Am Heart J 2013; 165(3): 338-343. Go to original source... Go to PubMed...
    25. Tousek P, Rokyta R, Tesarova J et al. Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study. Acute Card Care 2011; 13(3): 116-122. Go to original source... Go to PubMed...
    26. Rokyta R, Pechman V, Tousek P et al. Routine pretreatment with abciximab versus standard periprocedural therapy in mechanically ventilated cardiogenic shock patients undergoing primary percutaneous coronary intervention: Subanalysis of the PRAGUE-7 study. Exp Clin Cardiol 2013; 18(2): 81-84.
    27. De Backer D, Biston P, Devriendt J et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362(9): 779-789. Go to original source... Go to PubMed...
    28. Thiele H, Zeymer U, Neumann FJ et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367(14): 1287-1296. Go to original source... Go to PubMed...
    29. Thiele H, Zeymer U, Neumann FJ et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013; 382(9905): 1638-1645. Go to original source... Go to PubMed...
    30. Kopřiva K, Ošťádal P, Mates M et al. Intraaortální balónková kontrapulzace v klinické kardiologii. Interv Akut Kardiol 2013; 12(3): 130-134.
    31. Rokyta jr. R, Tesařová J, Čech J et al. Intraaortální balónková kontrapulsace v intenzivní kardiologické péči. Cor et Vasa 2010; 52(3): 127-133. Go to original source...
    32. Sjauw KD, Engström AE, Vis MM et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J 2009; 30(4): 459-468. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.